Mazdutide (100mg)

Description

Mazdutide (IBI362) is a long-acting dual GLP-1 receptor / glucagon receptor co-agonist developed by Innovent Biologics in collaboration with Eli Lilly. It is a fatty acid-conjugated peptide with balanced agonist activity at both receptors, designed to leverage the complementary metabolic effects of GLP-1 (appetite suppression, insulin secretion) and glucagon (hepatic lipid oxidation, energy expenditure) for combined weight loss and metabolic benefit.

Why Researchers Select Mazdutide

Phase 2 and 3 clinical trials of Mazdutide in Chinese populations with obesity and type 2 diabetes have demonstrated substantial body weight reduction and significant improvements in lipid profiles and hepatic steatosis markers — providing a well-characterized clinical data foundation for translational research. In preclinical and mechanistic studies, the GLP-1/glucagon co-agonism profile makes it particularly relevant for NASH/MAFLD research (glucagon receptor activation drives hepatic fatty acid oxidation and reduces intrahepatic lipids) and energy expenditure modeling. The 100mg research quantity supports extended protocol work.

Common Research Applications

• Dual GLP-1R/GCGR co-agonism metabolic pathway studies
• NASH/MAFLD hepatic steatosis and lipid clearance research
• Energy expenditure and thermogenesis investigation
• Obesity and type 2 diabetes pathway combination research
• Comparative GLP-1 mono vs. GLP-1/GCG dual agonist studies

Molecular Profile

• Type: Fatty acid-conjugated dual GLP-1R/GCGR co-agonist | Alias: IBI362
• Purity: ≥98% HPLC | Form: Lyophilized

For Research Use Only. Not for human or veterinary use.